REG - Seed Innovations Ltd - Investee Company Update: Juvenescence Ltd

Seed InnovationsAnnouncement

22/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250522:nRSV6713Ja&default-theme=true

RNS Number : 6713J  Seed Innovations Limited  22 May 2025

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic
Law by virtue of the European Union (Withdrawal) Act 2018. Upon the
publication of this announcement, this inside information is now considered to
be in the public domain.

 

SEED Innovations Ltd / AIM: SEED / Sector: Closed End Investments

 

22 May 2025

SEED Innovations Limited

("SEED" or the "Company")

 

Investee Company Update: Juvenescence Ltd

 

$76m fundraise led by Abu Dhabi-based, global tech-enabled healthcare company
M42

 

SEED Innovations Ltd, the AIM-quoted investment company offering exposure to
disruptive, high-growth, life sciences and technology ventures typically
inaccessible to everyday investors, is pleased to announce that its portfolio
company, Juvenescence, has today announced the first closing of its Series B-1
fundraising, securing a total of $76m in a round led by Abu Dhabi-based,
global tech-enabled healthcare company M42.

 

SEED holds 128,205 ordinary shares in Juvenescence, representing approximately
0.55% of Juvenescence's issued share capital prior to this raise. SEED's
investment in Juvenescence is carried at approximately £2.4 Million and this
valuation is not affected by this fundraise.

 

Key Highlights:

•     Juvenescence has raised $76m at the First Close of its Series B-1
fundraise, led by cornerstone investor M42, along with follow-on investments
from existing investors

•     Juvenescence recently entered into a wider partnership with M42 to
identify and develop a pipeline of AI-enabled therapeutics to extend healthy
lifespan and advance the treatment of life-threatening diseases.

•     The financing will enable Juvenescence to progress its portfolio
of therapeutics into clinical development and deliver critical clinical
readouts for its core medicine pipeline.

•     The second close of the Series B-1 is anticipated to be completed
in Q3 2025.

 

Juvenescence's full announcement can be accessed here:
https://www.globenewswire.com/news-release/2025/05/21/3085420/0/en/Juvenescence-closes-76m-first-tranche-of-Series-B-1-financing-led-by-Abu-Dhabi-s-M42-alongside-strategic-partnership.html

 

- Ends -

 

For further information on the Company please visit: www.seedinnovations.co
(http://www.seedinnovations.co/)  or contact:

 

 Ed McDermott        SEED Innovations Ltd             E: info@seedinnovations.co 

 Lance de Jersey                                       
 James Biddle        Beaumont Cornish Limited,        T: (0)20 7628 3396

 Roland Cornish      Nomad                             
 Isabella Pierre     Shard Capital Partners LLP       T: (0)20 7186 9927

 Damon Heath         Broker
 Ana Ribeiro         St Brides Partners Ltd,          E: seed@stbridespartners.co.uk

 Isabel de Salis     Financial PR

 

NOTES

Seed Innovations Ltd

Seed Innovations Ltd is an AIM quoted investment company offering exposure to
disruptive, high-growth, life sciences and technology ventures typically
inaccessible to everyday investors. Its strategy focuses on identifying
early-stage opportunities with upcoming investment catalysts, alongside more
mature investments providing near-term liquidity. With a portfolio of such
investments and cash reserves, the Company is agile and poised to capitalise
swiftly on new investment opportunities.

 

Juvenescence

Juvenescence is a therapeutics and development company, currently creating
multiple therapeutics focused on improving and extending human lifespans. The
Juvenescence team comprises proven and seasoned experts in drug development,
strategy, structure, commercialisation and finance.

 

The Company's approach centres around developing medicines that target core
pathways of aging to not only treat but prevent age-related diseases, ensuring
that longevity comes with enhanced quality of life. By focusing on early
disease intervention and prevention, Juvenescence are committed to
transforming how we age, ensuring that added years are healthy and fulfilling.

 

M42

M42 is a global health champion powered by artificial intelligence (AI),
technology and genomics to advance innovation in health for people and the
planet. Headquartered in Abu Dhabi, M42 combines its specialised,
state-of-the-art facilities with integrated health solutions like genomics and
biobanks, and harnesses advanced technologies to deliver precise, preventive
and predictive care, to impactfully disrupt traditional healthcare models and
positively impact lives globally.

 

Established in 2022, following the coming together of G42 Healthcare and
Mubadala Health, M42 has more than 480 facilities in 26 countries and over
20,000 employees. M42 includes renowned healthcare providers including
Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London
Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital
Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu
Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global
tech-enabled healthcare company operating Malaffi.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUAUNRVKUVUAR